Big Biotech is here — and it’s starting to look a lot like Big Pharma
By Meghana Keshavan,
STAT News
| 06. 06. 2016
Move over, Big Pharma. Big Biotech is coming for you.
As drug developers and investors from around the world gather in San Francisco this week for the annual BIO International Convention, a new look at the biotech industry shows the biggest players are starting to behave more and more like pharmaceutical giants.
There are 17 biotech companies in the US that generate more than $500 million per year in revenue. And they’re increasingly focused on buying innovative new products through mergers and acquisitions, rather than developing them in house, according to a report from EY (formerly Ernst & Young) released Monday.
“We now have multiple big biotechs that have the financial firepower to compete with big pharma,” said Ellen Licking, a senior analyst in EY’s life sciences practice.
Continue reading on STAT News
Image via Flickr
Related Articles
By Jennifer Denbow, Guest Contributor
| 10.29.2026
Almost every day I am reminded that we are in the midst of a fertility panic. Whether it’s the Vice President exhorting Americans to have more babies or The New York Times running yet another story about the fertility cliff, fear about falling fertility rates is everywhere. While centrally concerned with declining rates of childbearing, Anna Louie Sussman’s new book, Inconceivable: The Impossibility of Family in an Age of Uncertainty, is a welcome antidote to the panic.
Sussman has written...
By Anna Louie Sussman, The New Republic | 10.26.2026
There’s a certain kind of novel that’s not quite apocalyptic enough to be science fiction, but just far-fetched enough to be speculative. No one is from outer space; society has not yet been carved up into a hierarchy of groups...
By Ariana Aspuru and Noel King, Vox | 10.14.2026
For some couples, surrogacy is a miracle: an opportunity to have a child even if they’re unable to conceive one naturally. But it’s also big business. Not only is surrogacy expensive — think six figures — but it’s also largely...
By Sonia Suter and Naomi Cahn, The Conversation | 10.09.2026
